Endocrine and reproductive responses of male and female cattle to agonists of gonadotrophin-releasing hormone

M. J. D'Occhio and W. J. Aspden

Animal Sciences and Production Group, Centre for Primary Industries Research, Central Queensland University, Rockhampton, Queensland 4702, Australia

The pituitary response in cattle to treatment with GnRH agonist has two phases. In the acute phase secretion of LH is increased, while the chronic phase is characterized by a downregulation of GnRH receptors and insensitivity of gonadotrophs to natural sequence GnRH. After long-term treatment with GnRH agonist, cattle do not have pulsatile secretion of LH but maintain basal LH. This is associated with reduced pituitary contents of LH, LH mRNA, FSH and FSH mRNA. Long-term treatment of bulls with GnRH agonist results in an increase in testicular LH receptors and high plasma testosterone. Heifers treated with a GnRH agonist from early in the oestrous cycle develop a larger corpus luteum and secrete more progesterone. Increased steroidogenesis is reflected in increased steroid acute regulatory (StAR) protein and steroidogenic enzymes in the testes and corpus luteum. GnRH agonists have potential as novel strategies for reproductive management in cattle. A GnRH agonist bioimplant was recently used to block the LH surge after FSH stimulation of follicle growth in heifers. Ovulation was induced by injection of LH, and heifers were inseminated relative to the LH injection. This GnRH agonist-LH protocol provides a model for studying the gonadotrophin requirements for follicular growth and oocyte maturation in cattle, and will enable controlled in vivo maturation of oocytes before recovery for in vitro procedures.

Introduction

Gonadotrophin releasing hormone (GnRH) is a ten amino acid neuropeptide that initiates the cascade of reproductive hormones in mammals. Major reproductive events including the onset of puberty and ovulation rely on increases in GnRH secretion. Increased release of GnRH into hypothalano-hypophyseal portal vessels results in greater secretion of LH and FSH and enhanced gonadal function. The importance of GnRH for reproductive function has focused attention on this neuropeptide for reproductive therapies in cattle (Thatcher et al., 1993).

Agonists of GnRH were developed initially to treat hypogonadism resulting from insufficient endogenous secretion of GnRH. Typical structural features of GnRH agonists that distinguish them from natural sequence GnRH are substitution of glycine at position 6 of the peptide with a D-amino acid (e.g. D-tryptophan) and removal of glycine from the amino terminus. Substitution with a D-amino acid at position 6 increases the half-life of GnRH agonists in circulation, and removal of the amino terminal glycine increases affinity for the GnRH receptor (Karten and Rivier, 1986).

It was recognized early in the development of GnRH agonists that the reproductive response was dependent on dose of agonist and duration of treatment. The acute response, irrespective of dose, was characterized by increased gonadotrophin secretion (Chenuault et al., 1990). Chronic treatment with relatively high doses of GnRH agonist resulted in suppressed gonadotrophin secretion (Lahlou et al., 1987). The latter was due to downregulation of GnRH receptors on
Table 1. Anterior pituitary contents of LH and FSH (ng mg⁻¹ anterior pituitary) in intact bulls and castrated bulls (steers) treated with GnRH agonist

|                  | LH                  | FSH                  |
|------------------|---------------------|----------------------|
|                  | Control             | GnRH agonist         | Control             | GnRH agonist         |
| Bulls (n = 4)    | 450                 | 25 (P < 0.01)        | 950                 | 50 (P < 0.05)        |
| Bulls (n = 4–5)  | 553                 | 33 (P < 0.001)       | –                   | –                    |
| Steers (n = 8–11)| 228                 | 26 (P < 0.001)       | 1515                | 1390 (P > 0.05)      |

Values are means.

*Melson et al., 1986; Aspden et al., 1997a, b; Aspden et al., 1996.

gonadotrophs (Hazum and Conn, 1988) and an uncoupling (desensitisation) of second messenger systems within these cells (Huckle and Conn, 1988; Hawes et al., 1992).

This review provides an overview of the endocrine and molecular features of the responses of the anterior pituitary and gonads in cattle to treatment with GnRH agonists. Applications for GnRH agonists in the reproductive management of cattle also are considered.

**Neuroendocrine Response to GnRH Agonist Treatment**

Release of endogenous GnRH into hypothalamo–hypophyseal portal vessels in bull calves occurred in a pulsatile manner (Rodriguez and Wise, 1989). From this observation in male cattle and general patterns of LH release in female cattle, it can be assumed that GnRH release in cattle is pulsatile. In male sheep, treatment with GnRH agonist did not influence GnRH secretory patterns (Caraty et al., 1990). It would appear, therefore, that GnRH agonist treatment does not influence the activity of hypothalamic GnRH secreting neurones. This conclusion is consistent with the major known effects of GnRH agonists at the anterior pituitary gland, which are discussed below.

**Anterior Pituitary Response to GnRH Agonist Treatment**

The major direct effects of GnRH agonists within the reproductive axis appear to be actions at pituitary gonadotrophs (Hazum and Conn, 1988; Huckle and Conn, 1988). Bulls treated with the GnRH agonist nafarelin had reduced pituitary GnRH receptors after treatment for 15 days (Melson et al., 1986). This was consistent with the classical downregulation of GnRH receptors induced by GnRH agonists (Hazum and Conn, 1988). Studies on second messenger uncoupling (desensitization) (Huckle and Conn, 1988; Hawes et al., 1992) have not been conducted in cattle. However, these studies should be considered, as bulls and heifers treated with GnRH agonists maintain basal secretion of LH (discussed below). This result differs from the significant reduction in circulating LH seen in most species during agonist treatment (D'Occhio and Aspden, 1996).

Pituitary contents of LH (Table 1) and LH mRNA (Table 2) were reduced in intact bulls treated with GnRH agonist. This was associated with a lack of pulsatile secretion of LH (Melson et al., 1986) but maintenance of basal LH secretion (D'Occhio and Aspden, 1996; Aspden et al., 1997a, b; Aspden et al., 1998). In an intensive study of LH secretory patterns in bulls treated with the GnRH agonist nafarelin, it was confirmed that basal LH secretion in bulls is slightly but significantly increased during agonist treatment (Jimenez-Severiano et al., 1998). Similar increases in basal plasma LH were observed in heifers treated with leuprolide (Evans and Rawlings, 1994) and buserelin (Gong et al., 1995).

An effect of GnRH agonist on pituitary LH in cattle was demonstrated clearly using castrated bulls (Aspden et al., 1996), which have an increased secretion of LH and provide a useful experimental model to demonstrate any decreases in circulating LH (Fig. 1), and pituitary contents of LH and LH mRNA, which might occur during treatment with deslorelin. Although plasma LH
Table 2. Anterior pituitary contents of LH mRNA and FSH mRNA (mean arbitrary relative units) in intact bulls and castrated bulls (steers) treated with the GnRH agonist deslorelin

|                  | LH β-subunit mRNA | FSH β-subunit mRNA |
|------------------|-------------------|-------------------|
|                  | Control           | GnRH agonist      | Control           | GnRH agonist      |
| Bulls* (n = 4–5) | 0.65              | 0.22 (P = 0.003)  | –                 | –                 |
| Steers* (n = 8–11) | 1.56           | 0.08 (P < 0.001)  | 1.01              | 0.34 (P < 0.001)  |

Values are means.

*Aspden et al., 1997a; †Aspden et al., 1996.

Fig. 1. Longitudinal profiles of plasma (a) LH and (b) FSH in control (open circles) castrated bulls (steers) and steers treated with the GnRH agonist deslorelin (solid circles) commencing on day 0. Results are means ±SEM = 8 (Aspden et al., 1996).

was reduced in castrated bulls treated with agonist, basal secretion was maintained, similar to the finding in intact bulls (Fig. 1). The understanding that has emerged from GnRH agonist studies in cattle, therefore, is that pulsatile secretion of LH is blocked, which is consistent with GnRH receptor downregulation, but basal LH secretion is tonically increased (Evans and Rawlings, 1994; Jimenez-Severiano et al., 1998).

The mechanism(s) that promotes increased basal secretion of LH in cattle treated with GnRH agonist has not been defined. The basal secretion could be constitutive and does not require typical second messenger pathways (Huckle and Conn, 1988). Alternatively, GnRH agonists may stimulate second messenger pathways in cattle to maintain increased basal LH secretion. The latter suggestion might be considered inconsistent with the downregulation of GnRH receptors in cattle during agonist treatment. Endogenous GnRH is not required for continued secretion of LH in bulls treated with GnRH agonist, as bulls treated with agonist, and simultaneously actively immunized against GnRH, maintained basal secretion of LH (Aspden et al., 1997b).

Treatment of intact bulls with the GnRH agonist nafarelin caused a decrease in pituitary FSH content (Table 1). In castrated bulls, treatment with deslorelin was associated with a decrease in FSH mRNA (Table 2) but there was no apparent change in pituitary FSH content (Table 1). The latter observation was inconsistent with the reduction in plasma FSH in castrated bulls during treatment with deslorelin (Fig. 1).

The response of the pituitary to natural sequence GnRH is reinstated over several weeks after treatment with GnRH agonist in bulls (Bergfeld et al., 1996a) and heifers (Bergfeld et al., 1996b). It is not known whether the gradual recovery of pituitary responsiveness to GnRH is related to a gradual replenishment of GnRH receptors on gonadotroph cells, or to a gradual re-establishment of second
Table 3. Volume fractions and absolute volume (ml) per testis of seminiferous epithelium, lumen and interstitium for control bulls and bulls treated with deslorelin.

|                        | Volume fraction | Absolute volume per testis |
|------------------------|-----------------|----------------------------|
|                        | Seminiferous    | Lumen | Interstitium | Seminiferous    | Lumen | Interstitium |
| Control                | 0.693 ± 0.024a  | 0.116 ± 0.018a | 0.192 ± 0.015a | 119.5 ± 5.9a   | 19.8 ± 7.0a | 33.3 ± 3.6a |
| Deslorelin             | 0.707 ± 0.014a  | 0.110 ± 0.013a | 0.183 ± 0.007a | 168.0 ± 12.5a  | 27.1 ± 4.1a | 43.4 ± 3.4a |

Results are means ±SEM (n = 6).

a,bMeans within columns without a common superscript are significantly different (P < 0.01).

Means within columns with a common superscript are not significantly different (P > 0.05).

messenger pathways within gonadotroph cells (Gorospe and Conn, 1988). Consistent with a gradual return to normal pituitary function after GnRH agonist treatment, post-pubertal heifers treated with a deslorelin bioimplant for 10, 28 or 56 days ovulated approximately 20 days after treatment (D'Occhio and Kinder, 1995; D'Occhio et al., 1996). Heifers infused with buserelin for 48 days displayed oestrus 8–11 days after treatment, but a preovulatory surge release of LH had not occurred 22 days after treatment (Gong et al., 1996). In young bulls, treatment with leuprolide from 6 to 20 weeks of age delayed the occurrence of a prepubertal rise in plasma LH and testosterone by 4 weeks, from 20 weeks to 24 weeks (Chandolia et al., 1997).

Gonadal Responses to GnRH Agonist Treatment

Male cattle

Testosterone secretion, LH receptors and testis growth. The outstanding feature of the response in bulls to treatment with GnRH agonist is an increase in the secretion of testosterone which is maintained for the duration of treatment, irrespective of the dose of agonist (D'Occhio and Aspden, 1996). Increased testosterone secretion in bulls during agonist treatment was consistently demonstrated for deslorelin (Bergfeld et al., 1996a; D'Occhio and Aspden, 1996; Aspden et al., 1997a,b; Aspden et al., 1998), nafarelin (Melson et al., 1986), buserelin (Rechenberg et al., 1986) and leuprolide (Ronayne et al., 1993). However, relatively young bulls treated with leuprolide had reduced plasma concentrations of testosterone (Chandolia et al., 1997).

In a long-term study, 20-month-old Brahman and Brahman × Hereford Shorthorn bulls treated with deslorelin maintained high plasma testosterone for more than 120 days (D'Occhio and Aspden, 1996). Over this period, bulls receiving GnRH agonist showed a faster rate of testis growth and at the end of treatment had larger testes (Aspden et al., 1998). Increased testis size was associated with greater absolute volume per testis of seminiferous epithelium (Table 3). The numerical density of round spermatids in the testis was not increased in bulls treated with GnRH agonist, but the absolute number of round spermatids per testis was greater in bulls treated with agonist (23.5 ± 2.5 × 10⁹) than in control bulls (16.2 ± 1.4 × 10⁹). Increases in rate of testis growth in bulls during GnRH agonist treatment were not observed consistently in shorter-term studies (Melson et al., 1986; Ronayne et al., 1993). Notwithstanding the latter studies, chronic treatment with GnRH agonist may provide practical applications to influence testis growth and function in bulls, as discussed below.

Bulls treated with GnRH agonist had increased numbers of testicular LH receptors which might explain, in part, increased testosterone secretion (Melson et al., 1986). However, in vitro studies using rat Leydig cells, only approximately 1% LH receptor occupancy was required for a maximal testosterone response to gonadotrophin stimulation (Mendelson et al., 1975). It is possible, therefore, that increased testosterone secretion in bulls treated with GnRH agonist is due to a combination of
GnRH agonists in cattle

Increased LH receptors and tonically increased basal concentrations of LH. The increase in the number of LH receptors in bulls treated with agonist could be interpreted to mean that pulses of LH typically observed in bulls downregulate LH receptors in Leydig cells. The requirement of LH for increased testosterone secretion during GnRH agonist treatment was confirmed by the observation that plasma testosterone declined in bulls treated with agonist and simultaneously actively immunized against LH (Aspden et al., 1997b).

**StAR protein and steroidogenic enzymes in bulls.** Steroid acute regulatory (StAR) protein facilitates the transport of cholesterol from the cytoplasm to the inner mitochondrial membrane, which is the rate-limiting step in steroid biosynthesis (Stocco, 1997). StAR protein mRNA was demonstrated in bovine testis tissue (Piton et al., 1997). Testicular content of StAR protein was increased in bulls treated with GnRH agonist, and which had increased testicular testosterone content and enhanced testosterone secretion (Aspden et al., 1998). Major steroidogenic enzymes were similarly increased in bulls treated with GnRH agonist (Fig. 2). It would appear, therefore, that increased testosterone synthesis and secretion in bulls treated with GnRH agonist results from the stimulation of normal steroidogenic mechanisms in Leydig cells.

Bulls that had an increased plasma concentration of testosterone in response to chronic treatment with deslorelin showed a further acute increase in testosterone secretion subsequent to injection of human chorionic gonadotrophin (Table 4). This finding was interpreted as indicating that StAR protein and presumably steroidogenic enzymes are not maximally stimulated during GnRH agonist treatment in bulls.

**Female cattle**

**Follicles.** The acute increase in plasma LH that occurs at initiation of GnRH agonist treatment (Chenault et al., 1990) can induce ovulation of growing preovulatory follicles (Macmillan and Thatcher, 1991). Luteinization, without ovulation, also can be induced by treatment with GnRH agonist (Macmillan and Thatcher, 1991; Rettmer et al., 1992a). In Brahman heifers, ovulation was...
Table 4. Plasma concentrations of testosterone at commencement of treatment with deslorelin (day 0) and on day 56 of treatment, and changes in plasma concentrations of testosterone after intramuscular injection of hCG (2 000 iu; 0 min) on day 56 for control bulls and bulls treated with deslorelin

| Testosterone (ng ml⁻¹) | n  | Day 0  | Day 56  | Δ Testosterone |
|------------------------|----|--------|---------|---------------|
|                        |    |        | 0 min   | 120 min       |               |
| Control                | 6  | 1.6 ± 0.5a | 1.6 ± 0.4a | 3.7 ± 0.6a | 2.1 ± 0.7a |
| Deslorelin             | 8  | 1.9 ± 1.0a | 5.3 ± 1.4b | 11.1 ± 1.0c | 5.8 ± 1.4c |

Results are means ±SEM (M. J. D'Occhio, unpublished).

1 Increase in plasma concentration of testosterone after injection of hCG.
2, 3 Means within columns without a common superscript are significantly different (P < 0.05).
4, 5 Means within rows without a common superscript are significantly different (P < 0.05).

induced by GnRH agonist treatment on day 4 and day 6 of the oestrous cycle, but not day 2 or day 8 (Table 5). These findings were consistent with previous observations in which ovulation was consistently induced by treatment with GnRH agonist at about day 5 to day 6 of the oestrous cycle (Schmitt et al., 1996b). Practical applications of the ovulation-inducing response to acute GnRH agonist treatment are discussed below.

In post-pubertal heifers, the absence of pulsatile secretion of LH associated with continued treatment with GnRH agonist prevented the development of follicles (Gong et al., 1996) beyond the stage at which follicles acquire significant LH receptors and become LH-dependent (7-9 mm) (Bao et al., 1997). Subsequently, plasma FSH was suppressed and follicle growth was restricted to early stages of development (≤4 mm) (Gong et al., 1996). The GnRH agonist-treated heifer therefore provides an experimental model to study gonadotrophin requirements for growth, development and maturation of ovarian follicles.

In prepubertal heifers, treatment with deslorelin for 28 days was associated with increased plasma concentrations of oestradiol (Bergfeld et al., 1996b). This finding was analogous to increased testosterone secretion in bulls treated with GnRH agonist. There may be a common response mechanism in cattle that leads to increased gonadal steroidogenesis during GnRH agonist treatment. This suggestion is supported by increased progesterone secretion by the corpus luteum in heifers treated with GnRH agonist commencing early in the oestrous cycle (Thatcher et al., 1993; D'Occhio et al., 1996; Pitcher et al., 1997). Increased gonadal steroidogenesis in cattle receiving GnRH agonist could be related to the absence of pulsatile secretion of LH, but maintenance of tonically increased basal LH secretion (Evans and Rawlings, 1994; Jimenez-Severiano et al., 1998).

Since bulls had increased testicular LH receptors during GnRH agonist treatment (Melson et al., 1986), increased secretion of oestradiol in prepubertal heifers receiving agonist (Bergfeld et al., 1996b) may be due to increased stimulation of thecal cells by LH and a greater supply of androgen for follicular aromatization to oestradiol (Berndtson et al., 1995). However, this contention is not supported by the finding that post-pubertal heifers implanted with deslorelin, and undergoing superstimulation of ovarian follicle growth with FSH tended to have lower plasma concentrations of oestradiol (Fig. 3; heifers nos. 23, 50, 146 and 904). In the latter study, reduced secretion of oestradiol may have been due to reduced androgen precursor synthesis by thecal cells, due to a lack of pulsatile secretion of LH during stimulation of follicular growth with FSH.

It was suggested that the acute increase in LH that occurs when GnRH agonist treatment is initiated at the mid-luteal phase of the oestrous cycle (day 12-13) causes luteinization of follicles, which accounts for reduced secretion of oestradiol (Thatcher et al., 1993; Rettmer et al., 1992a). The steroidogenic response of follicles to GnRH agonist would appear to be influenced by age, ovarian status and other endocrine factors.

Heifers treated chronically with GnRH agonist cannot initiate an endogenous preovulatory surge release of LH and ovulation does not occur (D'Occhio et al., 1997). Chronic GnRH agonist
Fig. 3. Plasma concentrations of oestradiol for individual control heifers (left panel) and heifers treated with the GnRH agonist deslorelin (right panel). The latter heifers were implanted with a deslorelin bioimplant one week before treatment with FSH. FSH was used to stimulate ovarian follicle growth in both groups of heifers over 4 days, with FSH treatment ending on day 2 of the profiles (M. J. D'Occhio and J. E. Kinder, unpublished).
Table 5. Proportion of Brahman heifers that ovulated in response to treatment with a 
GnRH agonist bioimplant commencing on different days of the oestrous cycle

| Day of oestrous cycle | Diameter of the largest follicle (mm) | Proportion of heifers that ovulated |
|-----------------------|--------------------------------------|-----------------------------------|
| 2                     | 4.7 ± 0.3                            | 0/4                               |
| 4                     | 6.5 ± 0.7                            | 2/4                               |
| 6                     | 10.0 ± 0.0                           | 4/4                               |
| 8                     | 8.6 ± 0.9                            | 0/4                               |

Values are mean ± SEM (M. J. D'Occhio and F. Cremonesi, unpublished).

Table 6. Size of the corpus luteum and plasma concentrations of progesterone on day 13 of the oestrous cycle in control heifers and heifers treated with deslorelin from day 3 of the cycle

|                | n | Corpus luteum (g) | Plasma progesterone (ng ml⁻¹) |
|----------------|---|-------------------|------------------------------|
| Control        | 16 | 3.1 ± 0.2*        | 9.1 ± 1.3*                   |
| Deslorelin     | 16 | 4.2 ± 0.4*        | 18.9 ± 3.5*                  |

Results are means ± SEM.
*Pitcher et al. (1997).
*Means within columns without a common superscript are significantly different (P < 0.05).

Structure and function of the corpus luteum. Heifers treated chronically with GnRH agonist commencing early in the oestrous cycle (day 3) had a larger corpus luteum and secreted more progesterone than did untreated heifers (Table 6). Treatment with deslorelin was associated with higher basal plasma concentrations of LH (Pitcher et al., 1997) which could have contributed, in part, to increased size and function of the corpus luteum. The corpus luteum in heifers treated with deslorelin had a greater content of STAR protein and the steroidogenic enzyme, cytochrome P450 side-chain cleavage enzyme (P450scs; Pitcher et al., 1997). Treatment of heifers with buserelin early in the oestrous cycle caused an increase in the relative numbers of large luteal cells in the corpus luteum (Twagiramungu et al., 1995).

As noted above, heifers treated with GnRH agonist from about day 4 to day 6 of the oestrous cycle can ovulate and develop an accessory corpus luteum. In this situation, increased progesterone secretion during the oestrous cycle is contributed by the existing spontaneous corpus luteum and the accessory corpus luteum. The potential application of GnRH agonist treatment early in the oestrous cycle to increase plasma progesterone and enhance the likelihood of pregnancy recognition and conception is discussed below.

Application of GnRH Agonists in Cattle

Male cattle

Puberty and sperm production. Pubertal (20-month-old) Brahman (Bos indicus) bulls treated chronically with deslorelin for 120 days had a faster rate of testis growth and at the end of treatment
GnRH agonists in cattle

had a greater sperm production capacity than untreated bulls (Aspden et al., 1998). These findings indicate that reproductive development during the prepubertal period in bulls might be accelerated by chronic treatment with GnRH agonist. However, 5-month-old Freisian (Bos taurus) bulls treated with leuprolide for 56 days did not show enhanced testis growth (Ronayne et al., 1993). In another study, Holstein bulls (Bos taurus) treated with natural sequence GnRH from 1.5 to 3.0 months of age showed a delay in puberty (Miller and Amann, 1986). In addition, Hereford (Bos taurus) bulls treated with a slow-release formulation of leuprolide at approximately 1.5, 2.5 and 3.5 months of age had smaller testes and fewer spermatids at about 12 months of age (Chandolia et al., 1997). The present information therefore indicates that treatment with natural sequence GnRH or GnRH agonist occurring relatively early (1-3 months of age) may be detrimental to pubertal development, but treatment during the peripubertal period or after puberty may enhance testicular function.

Semen quality. Bulls treated with GnRH agonist had increased intratesticular testosterone and high plasma concentrations of testosterone (Aspden et al., 1998). It is possible that GnRH agonist treatment may be beneficial in situations in which testosterone production is reduced and is limiting to sperm production, semen quality or both factors. Increased testosterone synthesis in response to GnRH agonist treatment may enhance semen quality by effects within the testes, epididymides or accessory sex glands.

Female cattle

Treatment of cystic follicles. The acute increase in plasma LH that occurs at initiation of GnRH agonist treatment in female cattle (Chenault et al., 1990) can induce ovulation or luteinization of a cystic follicle (Thatcher et al., 1993). GnRH agonists are used for the treatment of cystic follicles, particularly in post-partum dairy cows.

Synchronization of oestrus. The capacity of acute treatment with GnRH and GnRH agonists to induce ovulation and formation of a corpus luteum has been used to develop oestrous synchronization protocols. A particularly successful protocol involves injections of GnRH or GnRH agonist, in combination with prostaglandin, to induce the emergence of a new dominant preovulatory follicle, and to control the time of ovulation for fixed-time insemination (Twagiramungu et al., 1995; Burke et al., 1996; Schmitt et al., 1996a; Pursley et al., 1997).

Induction of accessory corpus luteum. The relationship of conception rates in heifers to absolute concentrations of progesterone in circulation remains equivocal (Rettmer et al., 1992b; Macmillan and Peterson, 1993). If it is demonstrated that increased plasma concentrations of progesterone are associated with increased pregnancy rates, treatment with a GnRH agonist bioimplant commencing at about day 6 of the oestrous cycle may prove practical for inducing an accessory corpus luteum and increasing plasma progesterone, in combination with artificial insemination, embryo transfer, or both procedures. Treatment with GnRH agonist at about day 12 of the oestrous cycle after mating may extend the luteal phase and increase the opportunity for maternal recognition of pregnancy (Thatcher et al., 1993).

Post-partum anoestrus. The use of GnRH agonist treatment to induce ovulation during the post-partum period was examined extensively in beef and dairy cattle (D’Occhio et al., 1989; Roberge et al., 1992; Twagiramungu et al., 1995). Chronic treatment with agonist induced ovulation in post-partum anoestrous cows, but the life-span of the resulting corpus luteum was reduced. A corpus luteum of normal life-span could be induced if GnRH agonist treatment was preceded by progesterone priming (D’Occhio et al., 1989). Most previously anoestrous animals induced to ovulate with GnRH or GnRH agonist treatment did not initiate regular oestrous cycles. The application of
GnRH agonist treatment to induce ovulation in post-partum anoestrous cows would therefore appear to be restricted to situations in which it can be combined with progestagen priming and artificial insemination.

Superovulation

Sexually mature heifers and cows. A GnRH agonist bioimplant was recently used to develop a new protocol for multiple ovulation and embryo transfer (MOET) in cattle (D'Occhio et al., 1997). In the new protocol, donor heifers or cows are implanted with GnRH agonist approximately one week before commencement of FSH treatment. The preovulatory surge release of LH that typically occurs subsequent to FSH treatment is blocked due to the desensitizing actions of GnRH agonist described above and, accordingly, ovulation does not occur. However, ovulation can be induced by injection of exogenous LH (D'Occhio et al., 1997).

An outstanding feature of the GnRH agonist—LH protocol for MOET is that the time of ovulation is determined by programming the injection of exogenous LH (D'Occhio et al., 1998b). In a time-course study, it was found that optimal fertilization and recovery of embryos occurred when injection of exogenous LH was delayed by about 12 h, relative to normal occurrence of a preovulatory LH surge after stimulation with FSH (D'Occhio et al., 1997). It was considered that a delay in the occurrence of an LH surge allowed additional follicles to develop and acquire sufficient LH receptors for an ovulatory response.

The observation of oestrus subsequent to FSH stimulation is not required in the GnRH agonist—LH protocol, and donors are inseminated relative to the injection of exogenous LH (D'Occhio et al., 1997). In a recent study, typical rates of fertilization and embryo recovery were obtained after donor heifers received one insemination, 12 h after injection of exogenous LH (D'Occhio et al., 1998a).

Heifer calves

The ability to recover viable oocytes from heifer calves provides opportunities for genetic improvement in cattle (Davis et al., 1997). However, current production of viable embryos in vitro from oocytes of heifer calves remains relatively low and variable. Ovarian follicular waves are initiated early in the life span of heifer calves (Evans et al., 1994) and there is evidence to indicate that follicular dominance is also established early. These factors may contribute to variability in the follicular response of young heifers to stimulation with gonadotrophins. In addition, heifer calves can have a surge release of LH during stimulation of follicle growth, which may further contribute to the recovery of a heterogeneous population of oocytes (Macelllan et al., 1997).

A GnRH agonist bioimplant was recently used to block pulsatile secretion of LH and prevent the occurrence of a surge release of LH during stimulation of follicle growth with FSH in heifer calves (Macelllan et al., 1997, 1998). Calves treated with deslorelin had more follicles after stimulation with FSH, and this translated into a greater number of oocytes and embryos (Macelllan et al., 1997). This result was not observed in a subsequent study (Macelllan et al., 1998) and additional studies are required in larger numbers of heifer calves to determine whether treatment with a GnRH agonist confers an advantage in follicle growth, oocyte recovery and oocyte developmental competency.

In vivo oocyte maturation

The GnRH agonist—LH protocol for MOET described above (D'Occhio et al., 1997) provided an experimental model for examining whether it would be possible to achieve in vivo maturation of oocytes before recovery for in vitro procedures. Post-pubertal heifers were implanted with GnRH agonist, stimulated with FSH, and injected with LH 24 h after the final injection of FSH (Lindsey et al., 1998). Oocytes were recovered 12 h after injection of LH (i.e. before ovulation) and immediately exposed to spermatozoa for in vitro fertilization. The oocytes showed a fertilization potential and
Table 7. Fertilization rate (cleavage) and embryo development (blastocyst) for oocytes recovered after superstimulation of follicle growth with FSH in heifers treated with deslorelin, and heifers treated with deslorelin and treated with exogenous LH

|                | Total number of oocytes | Cleavage | Blastocyst |
|----------------|-------------------------|----------|------------|
| Deslorelin     | 9                       | 163      | 61 (42.3%)* | 9 (5.5%)* |
| Deslorelin + LH| 9                       | 112      | 61 (54.5%)* | 25 (22.3%)* |

Oocytes were recovered 12 h after injection of exogenous LH (Lindsey et al., 1998).

*Percentages within columns without a common superscript are significantly different (P < 0.05).

Embryo developmental competency that were typical of oocytes exposed to a conventional 24 h in vitro maturation before fertilization (Table 7). Oocytes obtained from heifers treated with GnRH agonist and FSH, but not injected with LH, had normal rates of fertilization but embryo developmental competency was compromised (Table 7). On the basis of these preliminary findings, the capacity for fertilization and embryo developmental competency would appear to have a differential requirement for exposure to pulsatile LH, a surge release of LH, or both. It is possible that oocyte cytoplasmic maturation may be more dependent on exposure to an LH surge than is nuclear maturation.

It would be of interest to examine whether in vivo maturation of oocytes using the GnRH agonist–LH protocol could be applied to heifer calves to increase embryo development rates. The GnRH agonist–LH protocol could be further applied to examine fundamental questions relating to the gonadotrophin requirements for normal follicle and oocyte growth and maturation in cattle.

Contraception

The absence of surge releases of LH in heifers and cows treated with GnRH agonist led to studies on the potential of a long-acting GnRH agonist bioimplant as a new contraceptive approach in female cattle (D’Occhio et al., 1996). In a recent study, a substantial contraceptive response was achieved over a period of approximately 12 months with a prototype GnRH agonist bioimplant (Table 8). The use of GnRH agonists provides opportunities for achieving a controlled, reversible suppression of fertility in female cattle.

Conclusion

The response of the anterior pituitary in cattle to treatment with GnRH agonist involves an acute phase (0 to 24 h) during which LH secretion is increased and a chronic phase during which pulsatile secretion of LH is suppressed, but basal release of LH is slightly but significantly increased. The mechanism(s) for continued release of LH during agonist treatment has not been elucidated, but may reflect non-stimulated constitutive release, or an action of the GnRH agonist on gonadotrophs to maintain functional second messenger pathways. An outstanding feature of the gonadal response in cattle treated with GnRH agonists is the increase in steroidogenic activity. This was demonstrated for increased testosterone secretion in bulls, increased oestradiol secretion in pre-pubertal heifers, and enhanced progesterone secretion in post-pubertal heifers treated with agonist commencing early in the oestrous cycle. The basis for the increase in steroidogenesis during agonist treatment is not understood but is likely to be related to tonically elevated basal secretion of LH which appears to be associated with an increase in gonadal LH receptors.

Both the acute and chronic phases of the LH response in cattle to treatment with GnRH agonist provide opportunities for practical applications of agonists. The acute increase in plasma LH that
Table 8. Ovarian activity in female cattle treated with a long-acting GnRH agonist bioimplant

| Duration of trial (days) | Number showing ovarian activity | Approximate duration of anoestrus in heifers and cows that showed a return of ovarian function (days) |
|-------------------------|---------------------------------|-------------------------------------------------|
| Trial 1 387             | 20 (26%)                        | 231 ± 19                                        |
| Trial 2 376             | 8 (10%)                         | 244 ± 13                                        |
| Trial 3 394             | 9 (9%)                          | 336 ± 3                                         |

Heifers and cows were grazed in the presence of bulls, and a return to cyclic ovarian activity was extrapolated from the time of conception (M. J. D'Occhio, G. Fordyce, T. Jubb and T. Whyte, unpublished). Contemporary untreated heifers and cows were introduced at regular intervals and conceived progressively during the trials (data not shown).

occurs at the beginning of agonist treatment has been used in the treatment of cystic follicles, in oestrous synchronisation protocols, and in new superovulation programmes. The lack of preovulatory surge releases of LH in heifers treated chronically with GnRH agonist will lead to the development of a long-acting contraceptive GnRH agonist bioimplant for female cattle. This will have application in the management of fertility in extensively managed beef herds and in the prevention of conception in pre-feedlot heifers. Other possible applications of GnRH agonists could be to increase progesterone secretion in combination with artificial insemination and embryo transfer to enhance conception rates, and to increase testosterone secretion chronically in bulls that have poor semen quality due to reduced testosterone synthesis.

The GnRH agonist-treated heifer will continue to provide an experimental model for studying gonadotrophin requirements for normal follicle and oocyte growth and development in cattle. These studies should lead to GnRH agonist-based protocols for in vivo maturation of oocytes before collection for in vitro procedures.

The studies undertaken by the authors were made possible by the generous provision of deslorelin bioimplants by Peptech Animal Health Pty Ltd, Sydney, Australia and the collaboration of T. E. Trigg, P. Sholer and J. Walsh; D. Miller (Vetrepharm (A/Asia) Pty Ltd, Melbourne, Australia) generously provided FSH (Folltropin-V®) and LH (Lutropin®) for the superovulation studies. Other support was provided by Central Queensland University, CSIRO Tropical Agriculture, and Meat and Livestock Australia Ltd.

References

Aspden WJ, Rao A, Scott PT, Clarke IJ, Trigg TE, Walsh J and D'Occhio MJ (1996) Direct actions of the luteinizing hormone-releasing hormone agonist, deslorelin, on anterior pituitary contents of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), LH and FSH subunit mRNA concentrations of LH and FSH in castrated male cattle Biology of Reproduction 55 386–392
Aspden WJ, Rao A, Rose K, Scott PT, Clarke IJ, Trigg TE, Walsh J and D'Occhio MJ (1997a) Differential responses in anterior pituitary luteinizing hormone (LH) and LHβ- and α-subunit mRNA, and plasma concentrations of LH and testosterone, in bulls treated with the LH-releasing hormone agonist deslorelin Domestic Animal Endocrinology 14 429–437
Aspden WJ, van Reenen N, Whyte TR, Maclellan LJ, Scott PT, Trigg TE, Walsh J and D'Occhio MJ (1997b) Increased testosterone secretion in bulls treated with a luteinizing hormone-releasing hormone (LHRH) agonist requires endogenous LH but not LHRH Domestic Animal Endocrinology 14 421–428
Aspden WJ, Rodgers RJ, Stocco DM, Scott PT, Wreford NG, Trigg TE, Walsh J and D'Occhio MJ (1998) Changes in testicular steroidogenic acute regulatory (StAR) protein, steroidogenic enzymes and testicular morphology associated with increased testosterone secretion in bulls receiving the luteinizing hormone releasing hormone agonist deslorelin Domestic Animal Endocrinology 15 227–236
Bao B, Garverick HA, Smith GW, Smith MF, Salfen BE and Youngquist RS (1997) Changes in messenger ribonucleic acid encoding luteinizing hormone receptor, cytochrome
D'Occhio MJ, Sudha G, Jillella D, Whyte T, Maclellan LJ, Walsh J, Trigg TE and Miller D (1996) Contained, desensitisation of the pituitary gland in young bulls after treatment with the luteinising hormone-releasing hormone agonist deslorelin. *Journal of Reproduction and Fertility* 54 769-775.

Bergfeld EG, D'Occhio MJ and Kinder JE (1996a) Pituitary function, ovarian follicular growth, and plasma concentrations of 17β-oestradiol and progesterone in prepubertal heifers during and after treatment with the luteinising hormone-releasing hormone agonist deslorelin. *Journal of Reproduction and Fertility* 54 776-782.

Berndtson AK, Vincent SE and Fortune JE (1995) Effects of gonadotrophin concentration on hormone production by theca interna and granulosa cells from bovine preovulatory follicles. *Journal of Reproduction and Fertility Suppl* 49 527-531.

Burke JM, de la Sota RJ, Risko CA, Staples CR, Schmitt EH-P and Thatcher WW (1986) Evaluation of timed insemination using a gonadotrophin-releasing hormone agonist in lactating dairy cows. *Journal of Dairy Science* 79 1385-1393.

Caraty A, Locatelli A, Delaleu B, Spitz IM, Schatz B and Bouchard (1995) Characteristics of pituitary gland in young bulls after treatment with the luteinising hormone-releasing hormone agonist deslorelin. *Biology of Reproduction* 54 45-52.

D'Occhio MJ and Kinder JE (1995) Failure of the LH-releasing hormone agonist to prevent the endogenous LH surge and injection of exogenous LH to induce ovulation in heifers superstimulated with FSH: a new model for superovulation. *Theriogenology* 47 601-613.

D'Occhio MJ, Jillella D, Whyte T, Trigg TE and Miller D (1996a) Tight synchrony of ovulation in superstimulated heifers induced to ovulate with LH: embryo recovery after a single insemination. *Theriogenology* 49 376 (Abstract).

D'Occhio MJ, Sudha G, Jillella D, Whyte T, Maclellan LJ, Walsh J, Trigg TE and Miller D (1996b) Close synchrony of ovulation in superstimulated heifers that have a downregulated anterior pituitary gland and are induced to ovulate with exogenous LH. *Theriogenology* 49 637-644.

Evans ACO and Rawlings NC (1994) Effects of a long-acting gonadotrophin-releasing hormone agonist (leuprolide) on ovarian follicular development in prepubertal heifer calves. *Canadian Journal of Animal Science* 74 649-656.

Evans ACO, Adams GP and Rawlings NC (1994) Follicular and hormonal development in prepubertal heifers from 2 to 36 weeks of age. *Journal of Reproduction and Fertility* 102 463-470.

Geng JG, Bramley TA, Gutierrez CG, Peters AR and Webb R (1995) Effects of chronic treatment with a gonadotrophin-releasing hormone agonist in bovine mature heifers. *Theriogenology* 43 2523-2529.

Gorospe WC and Conn PM (1988) Restoration of the LH secretory response in desensitized gonadotropes. *Molecular and Cellular Endocrinology* 59 101-110.

Hawes BE, Watts SB, Janovick JA, Blesdale JE and Conn PM (1992) Gonadotrophin-releasing hormone-stimulated intracellular Caizin packaged within a gonadotrophin-releasing hormone agonist in bovine pituitary cells. *Endocrinology* 1158-1168.

Hazzum EP and Conn PM (1988) Molecular mechanism of gonadotrophin-releasing hormone (GnRH) action I. The GnRH receptor. *Endocrine Reviews* 9 379-388.

Huckle WR and Conn PM (1988) Molecular mechanisms of gonadotrophin-releasing hormone action II. The effector system. *Endocrine Reviews* 9 387-395.

Jimenez-Severiano H, Mussard M, Ehnis L, Koch J, Zanella E, Lindsey B, Enright W, D'Occhio M and Kinder J (1998) Secretion of LH in bull calves treated with analogs of GnRH agonist deslorelin. *Journal of Reproduction and Fertility Suppl* 54 45-52.

Karten MJ and Rivier JE (1986) Gonadotrophin-releasing hormone analog design. Structure-function studies towards the development of agonists and antagonists. *Radioreceptor and perspectives Endocrine Reviews* 7 44-66.

Lahlou N, Roger M, Chausain JL, Feinstein MC, Sullian C, Toublanc JE, Schally AV and Scholler R (1987) Gonadotrophin and α-subunit secretion during long term pituitary suppression by α-Trp5-luteinising hormone-releasing hormone microcapsules as a treatment of precocious puberty. *Journal of Clinical Endocrinology and Metabolism* 67 946-953.

Lindsey BR, Maclellan LJ, Cremonesi S, Cremonesi F, Whyte TR, Aspden WJ, Kinder JE, Trigg TE, Miller DR and D'Occhio MJ (1998) Differential requirement for exposure of bovine oocytes to the pre-ovulatory LH surge for fertilisation and embryo development. In *Gametes: Development and Function* (eds A. Lauria, F. Gandolfi, G. Enzo and L. Gianaroli, Serono Symposium, Tbliboli S.r.l., Rome, 589 (Abstract).
Macmillan KL and Peterson AJ (1993) A new intravaginal progesterone releasing device for cattle (CIDR-B) for oestrous synchronisation, increasing pregnancy rates and the treatment of post-partum anoestrus. Animal Reproduction Science 33:1-25.

Macmillan KL and Thatcher WW (1991) Effects of an agonist of luteinizing hormone-releasing hormone on ovarian follicles in cattle I. Hormone concentrations and oestrous cycle length. Animal Reproduction Science 20:203-212.

Melson BE, Brown JL, Scheunemann HM, Tamavsky CK and Reeves JJ (1986) Elevation of serum testosterone during chronic LHRH agonist treatment in the bull. Journal of Animal Science 62:199-207.

Mendelson C, Dufau ML and Catt KJ (1975) Gonadotropin binding and stimulation of cyclic adenosine 3'5'-monophosphate and testosterone production in isolated Leydig cells. Journal of Biological Chemistry 250:8818-8823.

Miller CJ and Amann RF (1986) Effects of pulsatile injection of GnRH into 6- to 14-wk-old Holstein bulls. Journal of Animal Science 62:1332-1339.

Pillon N, Danefau I, Brisson C, Ethier J-F, Lussier JG and Silversides DW (1997) Porcine and bovine steroidogenic acute regulatory protein (StAR) gene expression during gestation. Endocrinology 138:1085-1091.

Pitcher DJ, Aspden WJ, Scott PJ, Rodgers RJ and D'Occhio MJ (1997) Pituitary desensitisation, increased progesterone secretion and changes in corpus luteum weight and steroidogenic enzyme content in heifers treated with the GnRH agonist deslorelin. Proceedings of the Australian Society for Reproductive Biology 28:28 (Abstract).

Pursley JR, Kosonok MR and Willbank MC (1997) Reproductive management of lactating dairy cows using synchronization of ova. Journal of Dairy Science 80:301-306.

Rechenberg WV, Sadow J and Klatt P (1986) Effect of long-term infusion of an LH-releasing hormone agonist on testicular function in bulls. Journal of Endocrinology 109:R3-R11.

Rittmer I, Stevenson JS and Corah LR (1992a) Endocrine responses and ovarian changes in inseminated dairy heifers after an injection of a GnRH agonist 11 to 13 days after estrus. Journal of Animal Science 70:308-317.

Rittmer I, Stevenson JS and Corah LR (1992b) Pregnancy rates in beef cattle after administering a GnRH agonist 11 to 14 days after insemination. Journal of Animal Science 70:7-12.

Roberge S, Schramm RD, Schally AV and Reeves JJ (1992) Reduced postpartum anestrus of suckled beef cows treated with microencapsulated luteinizing hormone-releasing hormone analog. Journal of Animal Science 70:2825-2830.

Rodriguez RE and Wisse ME (1989) Ontogeny of pulsatile secretion of gonadotropin-releasing hormone in the bull calf during infantile and pubertal development. Endocrinology 124:248-256.

Ronayne E, Enright WJ and Roche JF (1993) Effects of continuous administration of gonadotropin-releasing hormone (GnRH) or a potent GnRH analogue on blood luteinizing hormone and testosterone concentrations in prepubertal bulls. Domestic Animal Endocrinology 10:179-189.

Schmitt EF, Diaz T, Drost M and Thatcher WW (1996a) Use of a gonadotropin-releasing hormone agonist or human chorionic gonadotropin for timed insemination in cattle. Journal of Animal Science 74:1084-1091.

Schmitt EF, Diaz T, Barros CM, de la Soa RL, Drost M, Fredriksen EW, Staples CR, Thener R and Thatcher WW (1996b) Differential response of the luteal phase and fertility in cattle following ovulation of the first-wave follicle with human chorionic gonadotropin or an agonist of gonadotropin-releasing hormone. Journal of Animal Science 74:1074-1083.

Solcic DM (1997) A StAR search: implications in controlling steroidogenesis. Biology of Reproduction 56:328-336.

Thatcher WW, Drost M, Savio JD, Macmillan KL, Entwistle KW, Schmitt RL, de la Soa RL and Morris GR (1993) New clinical uses of GnRH and its analogues in cattle. Animal Reproduction Science 33:27-49.

Twagiramungu H, Gulibault LA and Dufour JJ (1995) Synchronization of ovarian follicular waves with a gonadotropin-releasing hormone agonist to increase the precision of estrus in cattle: a review. Journal of Animal Science 73:3141-3151.